Modjinou, Dodji V.
Krasnokutsky, Svetlana
Gyftopoulos, Soterios
Pike, Virginia C.
Karis, Elaine
Keenan, Robert T.
Lee, Kristen
Crittenden, Daria B.
Samuels, Jonathan
Pillinger, Michael H.
Funding for this research was provided by:
Savient Pharmaceuticals
Crealta Pharmaceuticals
National Center for Advancing Translational Sciences (1UL1TR001445)
Rheumatology Research Foundation
Article History
Received: 18 April 2017
Revised: 2 June 2017
Accepted: 7 June 2017
First Online: 16 June 2017
Compliance with ethical standards
:
: Dr. Pillinger is currently or has recently been a consultant for Crealta, Horizon, AstraZeneca, SOBI and Ironwood, serves as a study site investigator for Takeda. Dr. Krasnokutsky is currently or has recently been a consultant for Crealta, Horizon, AstraZeneca and Ironwood. Dr. Keenan is a consultant for Horizon, Ironwood and AstraZeneca. Dr. Crittenden is currently employed by Amgen. Dr. Karis has served on a speakers bureau for Takeda. No other author has any disclosures.